Iigo M, Shimizu I, Sagawa K
Chemotherapy Division, National Cancer Center Research Institute, Tokyo.
Jpn J Cancer Res. 1993 Jul;84(7):794-9. doi: 10.1111/j.1349-7006.1993.tb02046.x.
The effects of combination therapy including various antitumor agents and interferon on mice bearing hepatic metastases of colon carcinoma 26 were determined. Combined treatment with interferon-alpha A/D and carboplatin (CBDCA) was associated with a considerably more pronounced antitumor effect than was treatment with either drug alone. Murine interferon-beta and -gamma each also potentiated the antitumor activity of CBDCA. Combination therapy with interferon-alpha A/D and CBDCA also resulted in marked inhibition of hepatic metastasis of M5076 reticulum cell sarcoma. However, interferon-beta did not potentiate the antitumor activity of CBDCA against either subcutaneously implanted colon carcinoma 26 or pulmonary metastases of this tumor. Thus, in our model the combined administration of interferon and CBDCA was associated with a synergistic antitumor effect on hepatic metastases alone.
测定了包括各种抗肿瘤药物和干扰素在内的联合疗法对携带结肠癌26肝转移瘤小鼠的影响。与单独使用任何一种药物相比,αA/D型干扰素与卡铂(CBDCA)联合治疗具有明显更强的抗肿瘤作用。小鼠β型干扰素和γ型干扰素也均增强了CBDCA的抗肿瘤活性。αA/D型干扰素与CBDCA联合治疗还显著抑制了M5076网状细胞肉瘤的肝转移。然而,β型干扰素并未增强CBDCA对皮下接种的结肠癌26或该肿瘤肺转移的抗肿瘤活性。因此,在我们的模型中,干扰素与CBDCA联合给药仅对肝转移具有协同抗肿瘤作用。